亚宝药业
(600351)
| 流通市值：43.75亿 | | | 总市值：43.75亿 |
| 流通股本：7.00亿 | | | 总股本：7.00亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 614,533,394.31 | 2,686,037,568.67 | 2,121,509,818.79 | 1,443,686,437.98 |
| 营业收入 | 614,533,394.31 | 2,686,037,568.67 | 2,121,509,818.79 | 1,443,686,437.98 |
| 二、营业总成本 | 490,742,317.93 | 2,391,542,009.25 | 1,854,942,934.53 | 1,246,402,129.14 |
| 营业成本 | 289,256,463.32 | 1,297,853,138.07 | 1,023,628,071.91 | 659,977,902.29 |
| 税金及附加 | 8,831,932.81 | 34,045,339.09 | 26,570,623.72 | 18,402,929.58 |
| 销售费用 | 111,914,490.55 | 661,866,911.31 | 514,819,616.99 | 371,483,141.9 |
| 管理费用 | 59,383,276.34 | 259,067,167.24 | 200,458,781.73 | 127,507,085.8 |
| 研发费用 | 21,567,036.65 | 139,523,419.89 | 89,911,769.62 | 68,902,062.59 |
| 财务费用 | -210,881.74 | -813,966.35 | -445,929.44 | 129,006.98 |
| 其中:利息费用 | 644,477.45 | 5,347,631.23 | 4,660,671.71 | 3,616,649.05 |
| 其中:利息收入 | 892,131.73 | 6,448,673.81 | 5,310,753.39 | 3,625,373.96 |
| 加:公允价值变动收益 | 452,808.9 | -2,847,479.62 | 104,653.02 | 33,791.92 |
| 加:投资收益 | 603,719.9 | -188,368.93 | 82,208.83 | 135,319.7 |
| 资产处置收益 | 26,605.32 | 347,086.9 | 175,751.27 | 56,382.98 |
| 资产减值损失(新) | -3,095,784.05 | -42,162,919.81 | -6,806,022.31 | -5,988,652.34 |
| 信用减值损失(新) | -2,783,962.95 | 4,875,175.46 | 1,362,672.84 | -1,229,465.99 |
| 其他收益 | 9,327,516.84 | 45,434,066.6 | 26,887,624.07 | 21,849,900.86 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 128,321,980.34 | 299,953,120.02 | 288,373,771.98 | 212,141,585.97 |
| 加:营业外收入 | 616,576.88 | 1,634,646.67 | 1,158,966.09 | 1,031,924.49 |
| 减:营业外支出 | 633,172.16 | 9,479,638.95 | 5,521,404.09 | 367,397.88 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 128,305,385.06 | 292,108,127.74 | 284,011,333.98 | 212,806,112.58 |
| 减:所得税费用 | 22,236,917.2 | 68,192,627.05 | 55,543,479.47 | 37,614,335.23 |
| 六、净利润 | 106,068,467.86 | 223,915,500.69 | 228,467,854.51 | 175,191,777.35 |
| 持续经营净利润 | 106,068,467.86 | 223,915,500.69 | 228,467,854.51 | 175,191,777.35 |
| 归属于母公司股东的净利润 | 107,269,233.54 | 242,688,462.41 | 234,933,135.46 | 179,774,385.13 |
| 少数股东损益 | -1,200,765.68 | -18,772,961.72 | -6,465,280.95 | -4,582,607.78 |
| (一)基本每股收益 | 0.15 | 0.34 | 0.32 | 0.25 |
| 八、其他综合收益 | - | -1,288,990.13 | - | - |
| 归属于母公司股东的其他综合收益 | - | -1,288,990.13 | - | - |
| 九、综合收益总额 | 106,068,467.86 | 222,626,510.56 | 228,467,854.51 | 175,191,777.35 |
| 归属于母公司股东的综合收益总额 | 107,269,233.54 | 241,399,472.28 | 234,933,135.46 | 179,774,385.13 |
| 归属于少数股东的综合收益总额 | -1,200,765.68 | -18,772,961.72 | -6,465,280.95 | -4,582,607.78 |
| 公告日期 | 2025-04-26 | 2025-04-26 | 2024-10-25 | 2024-08-15 |
| 审计意见(境内) | | 标准无保留意见 | | |